Dinis-Oliveira Ricardo Jorge, Magalhães Teresa
IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal.
Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
J Clin Med. 2020 Mar 12;9(3):770. doi: 10.3390/jcm9030770.
About one-third of adult life is spent in the workplace. The use of psychoactive substances is a major preventable cause of morbidity and mortality. The consumption of psychoactive substances during or outside working hours greatly increases the frequency and severity of labor accidents, as well as the workers' poor general state of health and productivity, implying higher costs for enterprises. It is the responsibility of organizations to ensure the safety and health of their workers. These cannot be limited to traditional routine clinical exams, as other aspects also have an impact on health. Thus, prevention and intervention in the consumption of psychoactive substances (e.g., ethanol, opioids, central nervous system stimulants or depressants, hallucinogens, derivatives, dissociative substances, and inhalants) in labor activity should be considered as an investment of organizations and not as a cost, in view of the professional, personal, and family advantages for workers and employers, with a potential impact on productivity, security, health, and quality of life at work. Despite the extensive literature on the subject, each article generally focuses on one or another aspect of a very specific nature, not tackling the problem in a holistic way by confronting clinical, safety, and legal issues. This article presents a reflection on the legal, laboratorial, clinical, ethical, forensic, and safety concerns related to the consumption of psychoactive substances in the workplace, and can be a cross-cutting contribution to occupational medicine, forensic medicine, and insurance medicine, as well as for entrepreneurs, lawyers, judges, workers, and technicians from the public and private sectors that develop projects in this area. This discussion is based on general principles established internationally and highlights the role of the occupational healthcare system and other decision-making actors in the prevention and supervision of workplace psychoactive consumption.
成年人大约三分之一的人生是在工作场所度过的。使用精神活性物质是发病率和死亡率的一个主要可预防原因。在工作时间内或工作时间外使用精神活性物质会大大增加劳动事故的频率和严重程度,以及工人总体健康状况不佳和生产力低下的情况,这意味着企业成本更高。确保工人的安全和健康是各组织的责任。这些不能仅限于传统的常规临床检查,因为其他方面也会对健康产生影响。因此,鉴于对工人和雇主在职业、个人和家庭方面的益处,以及对生产力、安全、健康和工作生活质量的潜在影响,对劳动活动中精神活性物质(如乙醇、阿片类药物、中枢神经系统兴奋剂或抑制剂、致幻剂、衍生物、分离性物质和吸入剂)的消费进行预防和干预应被视为组织的一项投资,而不是一项成本。尽管关于这个主题有大量文献,但每篇文章通常只关注非常具体性质的一个或另一个方面,没有通过面对临床、安全和法律问题以全面的方式解决这个问题。本文对与工作场所精神活性物质消费相关的法律、实验室、临床、伦理、法医和安全问题进行了思考,并且可以对职业医学、法医学和保险医学做出贯穿各领域的贡献,对于在该领域开展项目的公共和私营部门的企业家、律师、法官、工人和技术人员也是如此。本讨论基于国际上确立的一般原则,并强调职业医疗保健系统和其他决策行为体在预防和监督工作场所精神活性物质消费方面的作用。